Advocates of the "morning after" emergency contraceptive drug are planning a reaction strategy to the FDA's delay of a decision on over-the-counter status for the drug despite an advisory panel's recommendation in December for OTC status. Saying it needed more time to review data, the agency put off a decision, prompting women's and public-health groups to accuse it of yielding to pressure from anti-contraception groups. Meanwhile, the Virginia House of Delegates took a preliminary step in voting to restrict the dispensing of such drugs.

Related Summaries